mRNA-2736

Phase 1Withdrawn

2 views this week 0 watching

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed or Refractory Multiple Myeloma

Conditions

Relapsed or Refractory Multiple Myeloma

Trial Timeline

Aug 15, 2023 → May 27, 2026

NCT ID

NCT05918250

About mRNA-2736

mRNA-2736 is a phase 1 stage product being developed by Moderna for Relapsed or Refractory Multiple Myeloma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05918250. Target conditions include Relapsed or Refractory Multiple Myeloma.

What happened to similar drugs?

2 of 20 similar drugs in Relapsed or Refractory Multiple Myeloma were approved

Approved (2) Terminated (2) Active (16)

✅Acalabrutinib capsuleAstraZenecaApproved

✅Drug: Carfilzomib + Dexamethasone + Drug: Carfilzomib + Lenalidomide + DexamethasoneAmgenApproved

🔄CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3

🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3

🔄AZD0120 + Daratumumab + Carfilzomib + Dexamethasone + Bortezomib + PomalidomideAstraZenecaPhase 3

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05918250	Phase 1	Withdrawn	Aug 15, 2023	May 27, 2026	Relapsed or Refractory Multiple Myeloma

Competing Products

20 competing products in Relapsed or Refractory Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-2808	Moderna	Phase 2	0
mRNA-2416	Moderna	Phase 2	0
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
VIP152 + BTKi	Vincerx Pharma	Phase 1	11
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	25
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
AC220	Daiichi Sankyo	Phase 1	29
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
Linsitinib	Astellas Pharma	Phase 2	35
AGS67E	Astellas Pharma	Phase 1	29
Mitoxantrone Hydrochloride Liposome & Enlonstobart	Sun Pharmaceutical	Phase 1/2	39
Lenvatinib	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
Eribulin mesylate	Eisai	Phase 2	35
ME-401	Kyowa Kirin	Phase 1	29
KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6	Kyowa Kirin	Phase 1	36
Mogamulizumab	Kyowa Kirin	Phase 2	39